Patents by Inventor Michael John Green
Michael John Green has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240157836Abstract: Improvements in energy distribution for electric vehicle (EV) energy delivery technologies are provided. An EV charging station management system optimizes the use of various sources of power for charging EVs. The optimizing may be based on current and/or forecasted EV charging demand, and the amount of greenhouse gas emissions produced by various sources to generate the power used for EV charging. In another embodiment, the optimizing may be based on current and/or forecasted EV charging demand, and current or forecasted cost of acquiring power from a power grid, which varies over time. The system may be configured to maximize earnings from EV charging at one or more charging stations.Type: ApplicationFiled: November 16, 2022Publication date: May 16, 2024Inventors: Christopher GALBRAITH, Keegan Michael John GREEN, Nasrin SADEGHIANPOURHAMAMI, Alexander LINCHIEH, Devashish PAUL, Mostafa FARROKHABADI
-
Patent number: 11718628Abstract: Provided herein are compounds comprising a three-ring core, such as compounds of Formula (X), Formula (X-A), Formula (X-Ai), Formula (X-B), Formula (X-Bi), Formula (Z), Formula (Z-A), Formula (Z-Ai), Formula (Z-B), Formula (Z-Bi), Formula (I), Formula (I-A), Formula (I-Ai), Formula (I-B), and Formula (I-Bi), and pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Also provided herein are methods of inhibiting a component of the sterol regulatory element binding protein (SREBP) pathway, such as an SREBP or SREBP cleavage activating protein (SCAP), using these compounds, or pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Further provided are methods of treating a disorder in a subject in need thereof, such as liver disease, non-alcoholic steatohepatitis, insulin resistance, or cancer.Type: GrantFiled: July 27, 2020Date of Patent: August 8, 2023Assignee: CAPULUS THERAPEUTICS, LLCInventors: Michael John Green, Barry Patrick Hart
-
Publication number: 20230225468Abstract: An adjustable mount and handle to support an umbrella onto a tube is disclosed. The present invention permits a user attach the umbrella to a tube or post and quickly and easily adjust the angle at any time. Thus, an individual can be shaded by the umbrella without having to manually hold the umbrella themselves.Type: ApplicationFiled: January 18, 2022Publication date: July 20, 2023Inventor: Michael John Green
-
Publication number: 20230147993Abstract: Provided herein are compounds comprising a four-ring core, such as compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Also provided herein are methods of inhibiting a component of the sterol regulatory element binding protein (SREBP) pathway, such as an SREBP or SREBP cleavage activating protein (SCAP), using these compounds, or pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Further provided are methods of treating a disorder in a subject in need thereof, such as liver disease, non-alcoholic steatohepatitis, insulin resistance, or cancer.Type: ApplicationFiled: May 12, 2022Publication date: May 11, 2023Inventors: Michael John GREEN, Barry Patrick HART
-
Publication number: 20220356170Abstract: Provided herein is the compound (3-chloro-4-(4-(2-(2-hydroxypropan-2-yl)pyridin-4-yl)thiophen-2-yl)phenyl)(4-hydroxypiperidin-1-yl)methanone (Compound 1), and pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Also provided herein are methods of inhibiting a component of the sterol regulatory element binding protein (SREBP) pathway, such as an SREBP or SREBP cleavage activating protein (SCAP), using Compound 1, or a pharmaceutically acceptable salt, solvate, tautomer, isotope, or isomer thereof. Further provided are methods of treating a disorder in a subject in need thereof, such as liver disease, non-alcoholic steatohepatitis, insulin resistance, or cancer.Type: ApplicationFiled: May 12, 2022Publication date: November 10, 2022Inventors: Michael John GREEN, Barry Patrick HART
-
Patent number: 11485725Abstract: The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to processes for preparing the same; a pharmaceutical composition and formulation containing a derivative of piperlongumine; and use of the derivatives and analogs for treating cancer.Type: GrantFiled: November 14, 2018Date of Patent: November 1, 2022Assignee: Auransa Inc.Inventors: Andrew Asher Protter, Michael John Green, Hak Jin Chang, Son Minh Pham, Sarvajit Chakravarty, Gregory R. Luedtke, Pek Yee Lum
-
Publication number: 20220056018Abstract: Provided herein are compounds comprising a three-ring core, such as compounds of Formula (I), Formula (I-i), Formula (I-A), Formula (I-A-i), Formula (I-A-i-1), Formula (I-B), Formula (I-B-i), Formula (I-B-i-1), Formula (II), Formula (II-i), Formula (II-A), Formula (II-A-i), Formula (II-A-i-1), Formula (II-B), Formula (II-B-i), and Formula (II-B-i-1) and pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Also provided herein are methods of inhibiting a component of the sterol regulatory element binding protein (SREBP) pathway, such as an SREBP or SREBP cleavage activating protein (SCAP), using these compounds, or pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Further provided are methods of treating a disorder in a subject in need thereof, such as liver disease, non-alcoholic steatohepatitis, insulin resistance, or cancer.Type: ApplicationFiled: July 26, 2021Publication date: February 24, 2022Inventors: Michael John GREEN, Barry Patrick HART
-
Patent number: 11173144Abstract: Adrenergic receptor modulating compounds and methods of using the same are provided. Also provided are methods of treating a subject for a disease or condition associated with an adrenergic receptor including administering a therapeutically effective amount of the subject compound. Aspects of the disclosure include a method of modulating an inflammatory pathway in a cell, such as the production of TNF-alpha in the cell. The method can include contacting a cell with ?1-selective adrenergic receptor modulating compound to selectively activate a cAMP pathway over a beta-arrestin pathway in the cell. Pharmaceutical compositions and kits which include the subject compounds are provided.Type: GrantFiled: May 12, 2017Date of Patent: November 16, 2021Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Mehrdad Shamloo, Alam Jahangir, Bitna Yi, Andrew Kelley Evans, Michael John Green
-
Publication number: 20210317140Abstract: The present application discloses compounds that are inhibitors of Btk, compounds that are inhibitors of PI3K?, and compounds that are dual inhibitors of both Btk and PI3K?. Also described are methods for synthesizing such inhibitors and methods for using such inhibitors for the treatment of diseases wherein inhibition of Btk and PI3K? provides a therapeutic benefit to a patient having the disease.Type: ApplicationFiled: October 17, 2014Publication date: October 14, 2021Applicant: Medivation Technologies, Inc.Inventors: Roopa RAI, Sarvajit CHAKRAVARTY, Michael John GREEN, Son Minh PHAM, Brahman PUJALA, Anil Kumar AGARWAL, Anjan Kumar NAYAK, Sweta KHARE, Rambabu GUGULOTH, Nitin Atmaram RANDIVE
-
Publication number: 20210198235Abstract: The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to processes for preparing the same; a pharmaceutical composition and formulation containing a derivative of piperlogumine; and use of the derivatives and analogs for treating cancer.Type: ApplicationFiled: November 14, 2018Publication date: July 1, 2021Inventors: Andrew Asher PROTTER, Michael John GREEN, Hak Jin CHANG, Son Minh PHAM, Sarvajit CHAKRAVARTY, Gregory R. LUEDTKE
-
Publication number: 20210047340Abstract: Provided herein are compounds comprising a three-ring core, such as compounds of Formula (X), Formula (X-A), Formula (X-Ai), Formula (X-B), Formula (X-Bi), Formula (Z), Formula (Z-A), Formula (Z-Ai), Formula (Z-B), Formula (Z-Bi), Formula (I), Formula (I-A), Formula (I-Ai), Formula (I-B), and Formula (I-Bi), and pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Also provided herein are methods of inhibiting a component of the sterol regulatory element binding protein (SREBP) pathway, such as an SREBP or SREBP cleavage activating protein (SCAP), using these compounds, or pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Further provided are methods of treating a disorder in a subject in need thereof, such as liver disease, non-alcoholic steatohepatitis, insulin resistance, or cancer.Type: ApplicationFiled: July 27, 2020Publication date: February 18, 2021Inventors: Michael John GREEN, Barry Patrick HART
-
Publication number: 20200237724Abstract: Adrenergic receptor modulating compounds and methods of using the same are provided. Also provided are methods of treating a subject for a disease or condition associated with an adrenergic receptor including administering a therapeutically effective amount of the subject compound. Aspects of the disclosure include a method of modulating an inflammatory pathway in a cell, such as the production of TNF-alpha in the cell. The method can include contacting a cell with ?1-selective adrenergic receptor modulating compound to selectively activate a cAMP pathway over a beta-arrestin pathway in the cell. Pharmaceutical compositions and kits which include the subject compounds are provided.Type: ApplicationFiled: May 12, 2017Publication date: July 30, 2020Inventors: Mehrdad Shamloo, Alam Jahangir, Bitna Yi, Andrew Kelley Evans, Michael John Green
-
Publication number: 20170137410Abstract: Fused cycloalkyl-pyrimidine compounds that are kinase inhibitors, such as multi-kinase inhibitors, are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused cycloalkyl-pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused cycloalkyl-pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.Type: ApplicationFiled: June 26, 2015Publication date: May 18, 2017Applicant: Medivation Technologies, IncInventors: Sarvajit CHAKRAVARTY, Roopa RAI, Michael John GREEN, Amantullah ANSARI, Anil Kumar AGARWAL
-
Patent number: 9550782Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor ?2A. The compounds may also bind to and are an antagonist of the adrenergic receptor ?2B; or the compounds are not antagonists of the adrenergic receptor ?2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.Type: GrantFiled: March 7, 2013Date of Patent: January 24, 2017Assignee: MEDIVATION TECHNOLOGIES, INC.Inventors: Andrew Asher Protter, Sarvajit Chakravarty, Rajendra Parasmal Jain, Michael John Green
-
Patent number: 9527854Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor ?2B antagonists. The compounds may also bind to and antagonize adrenergic receptor ?1B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.Type: GrantFiled: March 6, 2015Date of Patent: December 27, 2016Assignee: Medivation Technologies, Inc.Inventors: Andrew Asher Protter, Sarvajit Chakravarty, Rajendra Parasmal Jain, Michael John Green
-
Patent number: 9499519Abstract: Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. Fused pyrimidine compounds that are inhibitors of Trk receptors (e.g., Trk A, Trk B and Trk C) are provided also. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.Type: GrantFiled: December 26, 2013Date of Patent: November 22, 2016Assignee: MEDIVATION TECHNOLOGIES, INC.Inventors: Sarvajit Chakravarty, Roopa Rai, Michael John Green, Amantullah Ansari
-
Publication number: 20160272645Abstract: The present application discloses compounds that are inhibitors of Btk, compounds that are inhibitors of PI3K?, and compounds that are dual inhibitors of both Btk and PI3K?. Also described are methods for synthesizing such inhibitors and methods for using such inhibitors for the treatment of diseases wherein inhibition of Btk and PI3K? provides a therapeutic benefit to a patient having the disease.Type: ApplicationFiled: October 17, 2014Publication date: September 22, 2016Applicant: Medivation Technologies, Inc.Inventors: Roopa RAI, Sarvajit CHAKRAVARTY, Michael John GREEN, Son Minh PHAM, Brahmam PUJALA, Anil Kumar AGARWAL, Anjan Kumar NAYAK, Sweta KHARE, Rambabu GUGULOTH, Nitin Atmaram RANDIVE
-
Patent number: 9422267Abstract: The present invention provides fused pyrimidine compounds of the general Formula (I): or a salt thereof, wherein the variables are as defined in the specification. Fused pyrimidine compounds of the general Formula (I) are provided as kinase inhibitors, such as multi-kinase inhibitors. In one aspect, fused pyrimidine compounds of the general Formula (I) are provided as IGF-IR inhibitors. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compounds of the general Formula (I) and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound of the general Formula (I) or salt thereof and instructions for use, e.g., in a method of treating cancer.Type: GrantFiled: December 26, 2013Date of Patent: August 23, 2016Assignee: Medivation Technologies, Inc.Inventors: Sarvajit Chakravarty, Roopa Rai, Michael John Green
-
Publication number: 20160068513Abstract: Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. Fused pyrimidine compounds that are inhibitors of Trk receptors (e.g., Trk A, Trk B and Trk C) are provided also. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.Type: ApplicationFiled: December 26, 2013Publication date: March 10, 2016Applicant: MEDIVATION TECHNOLOGIES, INC.Inventors: Sarvajit CHAKRAVARTY, Roopa RAI, Michael John GREEN, Amantullah ANSARI
-
Publication number: 20150315188Abstract: Hydrogenated pyrido[4,3-b]indoles and pyrido[3,4-b]indoles are described. The compounds may bind to and are adrenergic receptor ?2B antagonists. The compounds may also bind to and antagonize adrenergic receptor ?1B. in The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.Type: ApplicationFiled: March 15, 2013Publication date: November 5, 2015Inventors: Andrew Asher PROTTER, Sarvajit CHAKRAVARTY, Michael John GREEN